Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.
Esnault C, Leblond V, Martin C, Desgranges A, Baltus CB, Aubrey N, Lakhrif Z, Lajoie L, Lantier L, Clémenceau B, Sarma B, Schrama J, Houben R, Schrama D, Hesbacher S, Gouilleux-Gruart V, Feng Y, Dimitrov D, Guyétant S, Berthon P, Viaud-Massuard MC, Samimi M, Touzé A, Kervarrec T. Esnault C, et al. Among authors: kervarrec t. Br J Dermatol. 2022 Feb;186(2):295-306. doi: 10.1111/bjd.20770. Epub 2021 Nov 2. Br J Dermatol. 2022. PMID: 34582565
Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology.
Esnault C, Schrama D, Houben R, Guyétant S, Desgranges A, Martin C, Berthon P, Viaud-Massuard MC, Touzé A, Kervarrec T, Samimi M. Esnault C, et al. Among authors: kervarrec t. Cancers (Basel). 2022 Feb 2;14(3):778. doi: 10.3390/cancers14030778. Cancers (Basel). 2022. PMID: 35159045 Free PMC article. Review.
Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer.
Lantier L, Poupée-Beaugé A, di Tommaso A, Ducournau C, Epardaud M, Lakhrif Z, Germon S, Debierre-Grockiego F, Mévélec MN, Battistoni A, Coënon L, Deluce-Kakwata-Nkor N, Velge-Roussel F, Beauvillain C, Baranek T, Lee GS, Kervarrec T, Touzé A, Moiré N, Dimier-Poisson I. Lantier L, et al. Among authors: kervarrec t. J Immunother Cancer. 2020 Nov;8(2):e001242. doi: 10.1136/jitc-2020-001242. J Immunother Cancer. 2020. PMID: 33257408 Free PMC article.
VEGF-A Inhibition as a Potential Therapeutic Approach in Merkel Cell Carcinoma.
Kervarrec T, Gaboriaud P, Tallet A, Leblond V, Arnold F, Berthon P, Schweinitzer S, Larcher T, Guyétant S, Schrama D, Houben R, Samimi M, Touzé A. Kervarrec T, et al. J Invest Dermatol. 2019 Mar;139(3):736-739. doi: 10.1016/j.jid.2018.08.029. Epub 2018 Oct 22. J Invest Dermatol. 2019. PMID: 30359576 Free article. No abstract available.
Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.
Ollier J, Kervarrec T, Samimi M, Benlalam H, Aumont P, Vivien R, Touzé A, Labarrière N, Vié H, Clémenceau B. Ollier J, et al. Among authors: kervarrec t. Cancer Immunol Immunother. 2018 Aug;67(8):1209-1219. doi: 10.1007/s00262-018-2176-2. Epub 2018 May 28. Cancer Immunol Immunother. 2018. PMID: 29808366 Free PMC article.
BerEP4 positivity in Merkel cell carcinoma: a potential diagnosis pitfall.
Kervarrec T, Tallegas M, Schrama D, Houben R, Ollier J, Clémenceau B, Vié H, Touzé A, Samimi M, Guyétant S. Kervarrec T, et al. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e707-e709. doi: 10.1111/jdv.16482. Epub 2020 Aug 3. J Eur Acad Dermatol Venereol. 2020. PMID: 32301152 No abstract available.
Immunobiology of Merkel cell carcinoma.
Samimi M, Kervarrec T, Touze A. Samimi M, et al. Among authors: kervarrec t. Curr Opin Oncol. 2020 Mar;32(2):114-121. doi: 10.1097/CCO.0000000000000608. Curr Opin Oncol. 2020. PMID: 31972727 Review.
83 results